- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04824079
Keynatinib in Treated Patients With NSCLC and Brain Metastases
November 4, 2023 updated by: Medolution Ltd.
Study of Keynatinib in Patients With Advanced Non-small Cell Lung Cancer With Brain Metastasis or Progression of Brain Metastasis After Treatment With EGFR Inhibitor(s)
The purpose of this study is to evaluate the safety and efficacy of Keynatinib capsules in patients with advanced non-small cell lung cancer (NSCLC) with brain metastasis or progression of brain metastasis after treatment with EGFR inhibitors.
As well as, to evaluate the penetration rate of Keynatinib in the Blood-Brain Barrier (BBB) and its PK characteristics, and the relationship between exposure levels with efficacy and safety.
Study Overview
Status
Recruiting
Intervention / Treatment
Detailed Description
This is a multicenter, non-randomized, open, single-arm, phase IIa trial investigating the security and effectiveness of Keynatinib in patients with advanced non-small cell lung cancer (NSCLC) with brain metastasis or progression of brain metastasis after treatment with EGFR inhibitors.
Study Type
Interventional
Enrollment (Estimated)
30
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100021
- Not yet recruiting
- Cancer Hospital, Chinese Academy of Medical Sciences
-
Contact:
- Yuankai Shi, PhD
- Phone Number: +86(010)-87788293
- Email: syuankaipumc@126.com
-
Principal Investigator:
- Yuankai Shi, PHD
-
Sub-Investigator:
- Shengyu Zhou, phD
-
-
Fujian
-
Fuzhou, Fujian, China, 350014
- Not yet recruiting
- Fujian Cancer Hospital
-
Contact:
- Wu Zhuang, phD
- Phone Number: +8613809500871
- Email: Zhuangwu2008@126.com
-
Principal Investigator:
- Wu Zhuang, phD
-
-
Henan
-
Zhengzhou, Henan, China, 450003
- Recruiting
- Henan Cancer Hospital
-
Contact:
- Huijuan Wu, MD
- Phone Number: +8613838528387
- Email: 13838528387@163.com
-
Principal Investigator:
- Huijuan Wu, MD
-
Sub-Investigator:
- Yanqiu Zhao, MD
-
-
Hunan
-
Changsha, Hunan, China, 410013
- Recruiting
- Hunan Cancer hospital
-
Contact:
- Jianhua Chen, MD
- Phone Number: +8613807488036
- Email: cjh_1000@163.com
-
Principal Investigator:
- Jianhua Chen, MD
-
-
Shandong
-
Jinan, Shandong, China, 250000
- Recruiting
- Shandong Cancer Hospital
-
Contact:
- Qisen Guo, phD
- Phone Number: +8613869199681
- Email: guoqs369@163.com
-
Principal Investigator:
- Qisen Guo, phD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Unlimited gender, age ≥ 18 years;
- Histologically or cytologically documented locally advanced, metastatic NSCLC (including L858R and/or Exon19 del mutation positive). The EGFR mutation assessed by local laboratory/or central laboratory via tissue/cytology or in plasma;
- Subjects should have the following conditions: a. (Cohort 1) Progression on any of the first or second generation EGFR inhibitors (gefitinib, erlotinib, afatinib, etc.).B. (Cohort 2) Progression on any third generation EGFR inhibitor (oxitinib, etc.), prior or non-prior treatment with any first or second generation EGFR inhibitor;
- The peripheral lesions did not progress after EGFR inhibitor treatment, but the occurrence of brain metastasis or progression of brain metastasis was confirmed by magnetic resonance imaging (MRI);
- As determined by the investigator, no final surgical resection or radiotherapy is expected for all lesions;
- Stable condition for at least 2 weeks prior to study medication without any corticosteroid or anticonvulsant therapy;
- The status score of Eastern Cooperative Oncology Group (ECOG) is 0 to 1 points, and there was no deterioration during the first 2 weeks of enrollment;
- Estimated survival time > 3 months;
- Sufficient bone marrow, liver, kidney and blood coagulation function;
- Subjects must be willing to use barrier contraception;
- Ability to provide informed consent, complete all study assessments and have complete medical record.
Exclusion Criteria:
- Have previously received chemotherapy, immunotherapy or any other systemic antitumor therapies within 4 weeks before the first administration; Have previously received EGFR-TKI within 5× half-life before the first administration; Have received oral fluorouracil and other small-molecule targeted drugs (whichever is longer) within 2 weeks or 5× half-life before enrollment; Within 2 weeks before enrollment, subjects had received palliative radiotherapy for non-target lesions for symptom relief, and traditional Chinese medicine (including Chinese patent medicine) for tumor indication;
- Have received whole brain radiation therapy;
- Only leptomeningeal metastasis are present;
- Historical intracranial hemorrhage not related to the tumor;
- Major organ surgery (excluding needle biopsy) or significant trauma have been performed within 4 weeks prior to enrollment;
- The drug or food with strong inhibition or induction of cytochrome P450 (CYP) isoenzyme CYP3A4 could not be stopped. The drug or food with strong inhibition or induction of cytochrome P450 (CYP) isoenzyme CYP3A4 had been used within 7 days before enrollment;
- Any unresolved toxicities from prior therapy greater than CTCAE 5.0 grade 1 at the time of enrollment with the exception of alopecia;
- Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the tablet or previous significant bowel resection that would preclude adequate absorption of Keynatinib;
- Past medical history of ILD, drug-induced ILD, radiation pneumonitis which required steroid treatment, or CT scan at baseline revealed the presence of idiopathic pulmonary fibrosis; Uncontrolled large pleural effusion or pericardial effusion; Active tuberculosis;
- Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses or active infection including hepatitis B, hepatitis C and HIV;
- Have a history of severe cardiovascular disease (NYHA cardiac function grade III or IV);
- Other primary malignancies (except cured basal cell carcinoma of the skin and carcinoma in situ of the cervix) within 5 years;
- Allergic to the active ingredient or excipient of Keynatinib;
- Pregnant or lactating women.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Keynatinib treatment group
All subjects shall be treated with Keynatinib twice a day (once every 12±3 hours), 20 mg each time, fasting within 2 hours before and 1 hour after taking the drug, and taking warm water when taking the drug.
Every 21 days is a treatment cycle .
|
The recommended dose is 20 mg Keynatinib twice a day until disease progression, unacceptable toxicity death occurs or withdraw from the study, whichever occurs first.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Response Rate
Time Frame: From start of treatment to time of progression (in CNS or non-CNS disease) , intolerable toxicity, withdrawal of informed consent or death, whichever occurs first,assessed up to 2 years.
|
The proportion of subjects whose optimal efficacy observed from the beginning of administration is CR or PR.
|
From start of treatment to time of progression (in CNS or non-CNS disease) , intolerable toxicity, withdrawal of informed consent or death, whichever occurs first,assessed up to 2 years.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 21, 2020
Primary Completion (Estimated)
April 22, 2025
Study Completion (Estimated)
July 22, 2025
Study Registration Dates
First Submitted
March 23, 2021
First Submitted That Met QC Criteria
March 26, 2021
First Posted (Actual)
April 1, 2021
Study Record Updates
Last Update Posted (Actual)
November 7, 2023
Last Update Submitted That Met QC Criteria
November 4, 2023
Last Verified
November 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Neoplastic Processes
- Central Nervous System Neoplasms
- Nervous System Neoplasms
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Neoplasm Metastasis
- Brain Neoplasms
Other Study ID Numbers
- MEDO-007-20002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Brain Metastases
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingRecurrent Brain Metastases | Progressive Brain MetastasesUnited States
-
AC Camargo Cancer CenterCarl Zeiss Meditec AGTerminatedBrain Metastases, Adult | Central Nervous System MetastasesBrazil
-
University of Vermont Medical CenterRecruiting
-
University Hospital, BrestRecruiting
-
Ohio State University Comprehensive Cancer CenterRecruitingBrain Metastases, AdultUnited States
-
Allegheny Singer Research Institute (also known...Elekta LimitedRecruitingBrain Metastases, AdultUnited States
-
BioMimetix JV, LLCNational Cancer Institute (NCI); Duke Cancer InstituteTerminatedMultiple Brain MetastasesUnited States
-
Guangdong 999 Brain HospitalJinan University Guangzhou; Beijing Tricision Biotherapeutics Inc; Trinomab Biotech...CompletedBrain Cancer | Neoplasm MetastasesChina
-
Royal Marsden NHS Foundation TrustNational Institute for Health Research, United KingdomUnknown
-
Rigshospitalet, DenmarkRecruitingCancer | Brain Metastases, AdultDenmark